Quince gets Nasdaq notice as equity sits at -$35.3M
Quince Therapeutics has fallen out of Nasdaq Global Select Market equity compliance and faces deadlines in late 2026 to present and execute a remediation plan.
Rhea-AI Filing Summary
Quince Therapeutics, Inc. (QNCX) reports that Nasdaq has notified the company it is not in compliance with Nasdaq Global Select Market Listing Rule 5450(b)(1)(A) because its stockholders’ equity was ($35,324,000) as of June 30, 2026, below the required $10,000,000 minimum.
The notice does not immediately affect trading, and the common stock continues to trade on the Nasdaq Global Select Market under the symbol QNCX. Quince has 45 days, until October 15, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days, to February 27, 2027, if Nasdaq accepts the plan. The company is evaluating alternatives and has also submitted an initial listing application that, if approved along with required stockholder matters, would support a transfer to the Nasdaq Capital Market under the new name IRulya Therapeutics Inc. and the symbol IRLA.
Positive
- None.
Negative
- Noncompliance with Nasdaq equity standard: stockholders’ equity of ($35,324,000) is far below the $10,000,000 minimum required for the Nasdaq Global Select Market, creating a risk of delisting if compliance is not restored.
- Timeline pressure to regain compliance: Quince has only 45 days to submit a remediation plan and up to 180 days to demonstrate compliance, after which its Global Select Market listing remains uncertain.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Stockholders’ equity: ($35,324,000)
Nasdaq minimum stockholders’ equity requirement: $10,000,000
Plan submission window: 45 calendar days
+1 more
4 metrics
Stockholders’ equity
($35,324,000)
As of June 30, 2026, based on the company’s Form 10-Q
Nasdaq minimum stockholders’ equity requirement
$10,000,000
Threshold under Nasdaq Listing Rule 5450(b)(1)(A) for Global Select Market
Plan submission window
45 calendar days
Time given to submit compliance plan, until October 15, 2026
Maximum extension period
180 calendar days
Potential extension to evidence compliance, until February 27, 2027
Key Terms
Nasdaq Global Select Market, Nasdaq Capital Market, stockholders’ equity, Nasdaq Listing Rule 5450(b)(1)(A), +2 more
6 terms
Nasdaq Global Select Market market
"the common stock will continue to trade on the Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
Nasdaq Capital Market market
"its common stock will trade on the Nasdaq Capital Market under the symbol"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
stockholders’ equity financial
"the Company’s stockholders’ equity was ($35,324,000)"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
Nasdaq Listing Rule 5450(b)(1)(A) regulatory
"not in compliance with Nasdaq Listing Rule 5450(b)(1)(A)"
Initial Listing Application regulatory
"the Company filed an initial listing application with Nasdaq"
An initial listing application is a company’s formal request to a stock exchange to have its shares offered publicly for the first time. Investors care because the application starts a review of the company’s finances, governance and disclosures—like a store deciding whether to carry a new product—so approval affects when shares become tradable, how much scrutiny the company faces, and the potential liquidity and price discovery for investors.
Required Company Stockholder Matters regulatory
"If the Required Company Stockholder Matters and the Initial Listing Application are approved"
FAQ
What Nasdaq listing issue did Quince Therapeutics (QNCX) disclose?
Quince disclosed that Nasdaq notified it of noncompliance with Listing Rule 5450(b)(1)(A) because stockholders’ equity was ($35,324,000), below the required $10,000,000 minimum for the Nasdaq Global Select Market.
What deadlines did Nasdaq give Quince Therapeutics (QNCX) to regain compliance?
Quince has 45 calendar days, until October 15, 2026, to submit a specific compliance plan. If Nasdaq accepts the plan, it may grant an extension of up to 180 days from the notice date, to February 27, 2027, to evidence compliance.
What stockholders’ equity level must Quince reach to comply with Nasdaq rules?
To regain compliance with Nasdaq Listing Rule 5450(b)(1)(A), Quince must have stockholders’ equity of at least $10,000,000. Its stockholders’ equity was reported as ($35,324,000) as of June 30, 2026.
Could Quince Therapeutics (QNCX) move to the Nasdaq Capital Market?
Yes. The company has filed an initial listing application with Nasdaq under Listing Rule 5110(a). If this and the Required Company Stockholder Matters are approved, it expects to list on the Nasdaq Capital Market as IRulya Therapeutics Inc., symbol IRLA.
Will Quince Therapeutics definitely regain Nasdaq compliance?
The company states there can be no assurance it will regain the minimum stockholders’ equity requirement, obtain approval of the initial listing application, secure the Required Company Stockholder Matters, or maintain compliance with other Nasdaq listing requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
